(VEVE) Vanguard FTSE Developed - Ratings and Ratios

Exchange: SW • Country: Switzerland • Currency: CHF • Type: Etf • ISIN: IE00BKX55T58

VEVE: Global, Large-Cap, Blend, Equity

The Vanguard FTSE Developed World UCITS ETF USD Distributing CHF is an exchange-traded fund that tracks the Morningstar Global TME NR USD index, providing investors with exposure to a broad range of global large-cap equities. With its origins in Switzerland, this ETF is designed to offer a diversified portfolio, blending stocks from various sectors and industries across developed markets.

From a technical standpoint, the ETFs price action suggests a potential bullish trend. The current price of 93.55 is above its 20-day Simple Moving Average (SMA) of 92.39, indicating a short-term uptrend. Moreover, the 50-day SMA of 88.85 is below the current price, further reinforcing this bullish sentiment. However, the ETFs price is slightly above its 200-day SMA of 92.91, suggesting a relatively stable long-term trend. The Average True Range (ATR) of 1.13, equivalent to 1.21%, indicates moderate volatility.

Fundamentally, the ETFs Assets Under Management (AUM) stand at 3459.88M CHF, demonstrating a significant presence in the market. As the ETF tracks the Morningstar Global TME NR USD index, its performance is closely tied to the overall global equity market. Given the current economic landscape, the ETF is likely to be influenced by factors such as global GDP growth, interest rates, and trade policies.

Based on the technical and fundamental data, a forecast for the Vanguard FTSE Developed World UCITS ETF USD Distributing CHF can be made. If the global economy continues to grow, and the current uptrend persists, the ETFs price may reach the upper end of its 52-week range, potentially testing the 101.03 level. Conversely, if the market experiences a downturn, the ETFs price may decline towards its 52-week low of 78.77. Therefore, investors may consider a buy-and-hold strategy, taking advantage of the ETFs diversification and the potential for long-term growth, while being mindful of the associated risks and market volatility.

Additional Sources for VEVE ETF

Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

VEVE ETF Overview

Market Cap in USD 4,302m
Category Global Large-Cap Blend Equity
TER 0.12%
IPO / Inception 2014-09-30

VEVE ETF Ratings

Growth Rating 54.3
Fundamental -
Dividend Rating 45.5
Rel. Strength -11
Analysts -
Fair Price Momentum 107.47 CHF
Fair Price DCF -

VEVE Dividends

Dividend Yield 12m 1.19%
Yield on Cost 5y 1.96%
Annual Growth 5y 5.20%
Payout Consistency 88.6%
Payout Ratio %

VEVE Growth Ratios

Growth Correlation 3m 39.2%
Growth Correlation 12m 25.6%
Growth Correlation 5y 70.8%
CAGR 5y 10.55%
CAGR/Max DD 5y 0.48
Sharpe Ratio 12m 0.53
Alpha -8.57
Beta 0.758
Volatility 12.61%
Current Volume 1.7k
Average Volume 20d 1.6k
What is the price of VEVE shares?
As of June 27, 2025, the stock is trading at CHF 91.90 with a total of 1,715 shares traded.
Over the past week, the price has changed by +0.26%, over one month by -0.04%, over three months by -2.28% and over the past year by +2.65%.
Is Vanguard FTSE Developed a good stock to buy?
Partly, yes. Based on ValueRay´s Analyses, Vanguard FTSE Developed (SW:VEVE) is currently (June 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 54.30 and therefor an somewhat technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VEVE is around 107.47 CHF . This means that VEVE is currently undervalued and has a potential upside of +16.94% (Margin of Safety).
Is VEVE a buy, sell or hold?
Vanguard FTSE Developed has no consensus analysts rating.
What are the forecasts for VEVE share price target?
According to our own proprietary Forecast Model, VEVE Vanguard FTSE Developed will be worth about 122.6 in June 2026. The stock is currently trading at 91.90. This means that the stock has a potential upside of +33.43%.
Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 122.6 33.4%